The OCD Study

Obsessive Compulsive Disorder (OCD)
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

The purpose of this study is to establish the efficacy and safety of the investigational medication as adjunctive therapy compared to placebo in people with OCD.

Enrolling Patients
Phase 3
102 Study Locations
Calendar icon in blue and white

Length of Study

12 weeks
Building icon in blue and white

# Study Visits

Icon of a person taking notes in blue and white

Post-study Follow Up

2 Weeks
Male and Female icon in blue and white

Who’s Included?

Adults; All genders

Flask icon in blue and white

Drug & Formulation


Dice icon in blue and white

Possibility of Placebo


OCD is a mental health disorder that occurs when a person gets caught in a cycle of obsessions and compulsions. Obsessions are unwanted, intrusive thoughts, images or urges that trigger intensely distressing feelings. Compulsions are behaviors an individual engages in to attempt to get rid of the obsessions and/or decrease their distress.

  • Participants Must:

  • Have a primary diagnosis of OCD as per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition as confirmed by the MINI at screening; the duration of the subject’s illness must be ≥ 1 year
  • Have an inadequate response to current standard of care medication defined as selective serotonin reuptake inhibitor (excluding fluvoxamine) or clomipramine treatment at an adequate and stable dose for at least 8 weeks prior to screening and at least 12 weeks at baseline (adequate dose defined by USPI labeling); an inadequate response as defined per the MGH-TRQ-OCD, there has been minimal or no meaningful clinical benefit as perceived by the subject
  • Be determined by the investigator to be medically stable at baseline/randomization as assessed by medical history, physical examination, laboratory test results and electrocardiogram testing. Subjects must be physically able and expected to complete the trial as designed
  • Participants Must Not:

  • Have a history of more than 2 previous failed or inadequate treatment classes given for an adequate duration at an adequate dose as defined by the MGH-TRQ-OCD
  • Have current or prior history of: bipolar I or II disorder, schizophrenia or other psychotic disorders, schizoaffective disorder, autism or autistic spectrum disorders, borderline personality disorder, antisocial personality disorder, Tourette’s disorder, body dysmorphic disorder, hoarding disorder; or psychosurgery, deep brain stimulation (DBS) or electroconvulsive therapy (ECT); or general medical condition that may confound safety and/or efficacy results
  • Have undergone previous treatment in a study with troriluzole

Learn more about the benefits of joining our OCD clinical trial and see if you qualify today!

Frequently Asked Questions

About 1,400 people will participate.

If you think you have OCD, a clinician will evaluate your eligibility.

This study is approximately 3 months and if your doctor thinks it may benefit you, you may have the opportunity to participate longer.

Learn more about the benefits of joining our OCD clinical trial and see if you qualify today!